Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
Phase 3positiveSacituzumab TirumotecanPembrolizumabPositive
AI Analysis
Summary
Kelun-Biotech announced that its Phase III OptiTROP-Lung06 trial met its primary endpoint, demonstrating that sacituzumab tirumotecan (sac-TMT) plus pembrolizumab superiority over standard immunotherapy plus chemotherapy as first-line treatment for PD-L1-negative non-squamous NSCLC. The trial showed significantly prolonged outcomes by replacing conventional pemetrexed/platinum chemotherapy with sac-TMT.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
OptiTROP-Lung06 Phase III trial met primary endpoint, demonstrating superiority of sac-TMT plus pembrolizumab versus standard of care (immunotherapy plus chemotherapy), with significantly prolonged outcomes
Importance:8/10
Sentiment:
0.75
Phase 3 dataoncologyNSCLCimmunotherapyADC
Related Companies
Read the original article
Published by PR Newswire Pharma on July 14, 2026 11:30 PM